Below are the most recently updated broker updates which include ratings and price targets for Accelerate Diagnostics, Inc. (AXDX).

04/11/2016 – Broker: BTIG Research Rating: buy New Target: 26 reiteration

03/24/2016 – Broker: JP Morgan Rating: overweight New Target: 17 newcoverage

01/08/2016 – Broker: William Blair Rating: outperform newcoverage

12/31/2015 – Broker: Piper Jaffray Rating: overweight New Target: 25 reiteration

The average price target from the most recent broker reports is 22.67

The stock decreased -1.69% (-0.20) during the last days session, reaching 11.61 and roughly 174970 shares were bought or sold by traders.

View other investors thoughts on Accelerate Diagnostics, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.